The Piper Jaffray price target for the stock is $26, and the consensus target is higher at $31. Repros closed Wednesday at $21.83. Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is running radio spots for its non 24 drug, Tasimelteon. New …
If you want a Stock Review on VNDA, VSTM, XLRN, or ZLAB then come over to http://dailystocktracker.com/register/ …
Many investors like to look for momentum in stocks, but this can be very tough to define. There is great debate …
For a hedged play on Vanda Pharmaceuticals (VNDA), MarketIntelligenceCenter.com’s option-trade picking algorithms recommend the Jun 15, 2018 $14 covered call for a net debit in the $12.89 area. That is also the break-even stock price …
Vanda Pharmaceuticals Inc. (VNDA) announced after the close Thursday that it has ... Vanda Pharmaceuticals gapped up Friday and climbed during the first hour of trade. The stock took out the session highs in late trade and closed up by …
WASHINGTON (AP) _ Vanda Pharmaceuticals Inc. (VNDA) on Wednesday reported a loss of $604,000 in its fourth quarter. The Washington-based company said it had a loss of 1 cent per share. Earnings, adjusted for amortization …
While Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) have appreciated 38 percent since the favorable U.S. Fanapt IP ruling on August 25, Jefferies’ Matthew J. Andrews believes that there could be potential for long-term upside to the …
Mr. Gian Piero Reverberi is Senior Vice President, Chief Compliance Officer of the Company. He was Senior Vice President, Acting Chief Commercial Officer and European General Manager from December 2015 to April 2016. Mr. …
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), a biopharmaceutical company ... Naked short selling is the illegal act …